Clinical trial
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell…
NCT00160043 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00160043 |
|---|---|
| Title | Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer. |
| Official title | Phase II Open-label Study to Investigate the Efficacy and Safety of PTK787/ZK 222584 Orally Administered Once Daily or Twice Daily at 1250 mg as Second-line Monotherapy in Patients With Stage IIIB or Stage IV Non-small-cell Lung Cancer (NSCLC) |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | SH T00268C, PTK787/ ZK 222584 |
| Enrollment | 112 |
| Start date | Mar 1, 2005 |
| Primary completion | Aug 1, 2007 |
| Completion | Nov 1, 2008 |
| First posted | Sep 12, 2005 |
| Last update posted | Dec 16, 2014 |
| Countries | France, Germany |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: